ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure RatesFirst Prospective Trial to Incorporate the Foresight Diagnostics's Investigational CLARITY™ Test to Identify Patients with LBCL Who Have Minimal Residual Disease (MRD) and are Likely to Relapse Following Standard 1L TreatmentUnique Profile of Investigational AlloCAR T™ Products May Expand Access to CAR T within Community Cancer Centers where Most 1L Patients are ManagedALPHA3 Expected to Co ...

Penny stocks carry a great deal of risk. It’s why investors are often told to steer clear of them. Many penny stocks typically trade over the counter and rarely on a major exchange. And about 90% of them fail. It’s why we include a warning at the tail-end of the article, and why the U.S. SEC has issued warnings against them. While you may get lucky and uncover the next Apple (NASDAQ:AAPL) or Advanced Micro Devices (NASDAQ:AMD) in the bunch, you have to dig through a lot of garbage. That’s not to say it’s im ...

SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced it will participate in the TD Cowen 5th Annual Oncology Innovation Summit. TD Cowen 5th Annual Oncology Innovation SummitTuesday, May 28, 20249:30am PT/12:30pm ET The webcast will be posted to the Company's website at www.allogene.com under the Inv ...

Allogene Therapeutics, Inc. (ALLO) registered a loss of 38 cents per share in first-quarter 2024, in line with the Zacks Consensus Estimate. In the year-ago quarter, the company reported a loss of 69 cents.ALLO recorded revenues of $0.02 million during the quarter, missing the Zacks Consensus Estimate of $0.04 million. Revenues were down 27% year over year.Quarter in DetailResearch & development (R&D) expenses were $52.3 million, down 35% from the year-ago quarter’s level.General and administrative (G&A) ex ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2024 Earnings Conference Call May 13, 2024 5:00 PM ET Company Participants Christine Cassiano - Chief Corporate Affairs & Brand Strategy Officer David Chang - President & Chief Executive Officer Geoff Parker - Chief Financial Officer Zachary Roberts - EVP, Research & Development and Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Tyler Van Buren - TD Cowen Salveen Richter - Goldman Sachs Reni Benjamin - Citizens JMP Luca Issi - RBC Capi ...

Financial Performance - Allogene Therapeutics reported a quarterly loss of $0.38 per share, which aligns with the Zacks Consensus Estimate, an improvement from a loss of $0.68 per share a year ago [1] - The company posted revenues of $0.02 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 47.62%, compared to revenues of $0.05 million in the same quarter last year [1] - Over the last four quarters, Allogene has surpassed consensus EPS estimates three times, but has not beaten consensus revenue estimates [1] Stock Performance - Allogene Therapeutics shares have declined approximately 14% since the beginning of the year, contrasting with the S&P 500's gain of 9.5% [2] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [4] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of $0.04 million, and for the current fiscal year, it is -$1.65 on revenues of $0.15 million [4] - The estimate revisions trend for Allogene Therapeutics is mixed, and future changes in estimates will be closely monitored following the recent earnings report [4] Industry Context - The Medical - Biomedical and Genetics industry, to which Allogene belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [5] - Another company in the same industry, Precigen, Inc., is expected to report a quarterly loss of $0.09 per share, reflecting a year-over-year change of +10%, with revenues anticipated to be $1.54 million, down 16.8% from the previous year [5][6]

SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwritten offering of 37,931,035 shares of its common stock at a price of $2.90 per share. The gross proceeds from this offering are expected to be approximately $110 million, before deducting the underwriting discount and comm ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________________ FORM 10-Q ________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 ...

Exhibit 99.1 Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update • Cemacabtagene Ansegedleucel (Cema-Cel) ◦ Expanded CD19 Oncology Rights to Include all EU Member States and the United Kingdom, Reinforcing Company’s Conviction in the Unique Opportunity in Large B Cell Lymphoma (LBCL) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) ▪ Extended Territory Rights Substantially Increase Market Opportunity in 1L Consolidation LBCL and R/R CLL From More Than $6 Bi ...

Cemacabtagene Ansegedleucel (Cema-Cel) Expanded CD19 Oncology Rights to Include all EU Member States and the United Kingdom, Reinforcing Company's Conviction in the Unique Opportunity in Large B Cell Lymphoma (LBCL) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Extended Territory Rights Substantially Increase Market Opportunity in 1L Consolidation LBCL and R/R CLL From More Than $6 Billion in the US to More Than $9.5 Billion in the Combined U.S., EU Member States and the United KingdomCon ...